| 產(chǎn)品編號(hào) | bsm-61219R |
| 英文名稱 | Midkine Recombinant Rabbit mAb |
| 中文名稱 | 中期因子/肝素結(jié)合生長(zhǎng)因子重組兔單抗 |
| 別 名 | MDK; FLJ27379; MK1; NEGF2; Midkine; NEGF2; ARAP. |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Recombinant |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | WB=1:1000-1:2000,IHC-P=1:100-1:200,IHC-F=1:100-1:200,IF=1:50-1:200,ICC/IF=1:50-1:200,IP=1:20-1:50
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 16 kDa |
| 檢測(cè)分子量 | 16 |
| 性 狀 | Liquid |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Midkine |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| 保存條件 | Store at 4℃ for short term. Store at -20℃ for long term. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Midkine, or MK, is a heparin-binding molecule involved in the regulation of growth and differentiation during embryogenesis. MK expression is tightly regulated during embryonic development by steroid receptors of the retinoic acid superfamily. The mature human MK protein is 118 amino acids in length and contains five intrachain disulfide bonds. MK is a non-glycosylated protein that shows greater than 87% identity between human and mouse. SWISS: P21741 Gene ID: 4192 中期因子(midkine, MK)具有多種生物學(xué)功能: 可促進(jìn)神經(jīng)軸突 的生長(zhǎng)和各種胚胎神經(jīng)元的存活,做為一種有絲分裂原,與腫瘤的發(fā)生密切相關(guān)，MK還有較強(qiáng)的 促血管生成特性, 經(jīng)研究證實(shí), MK可促進(jìn)內(nèi)皮細(xì)胞增殖并 提高血管的密度，在多種腫瘤組織和腫 瘤患者的血清中的水平都明顯升高。MK和多向促激素(p leiotro2 phin, PTN)同屬于一類新的結(jié)合肝素的生長(zhǎng)因子家 族。 |
| 產(chǎn)品圖片 |
Western blot analysis of Midkine Recombinant protein. Using Midkine (bsm-61219R) monoclonal antibody at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
